Olga L. Kochneva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Olga L. Kochneva has a total of 120 co-authors. Here are the top co-authors by number of shared publications:
- Elena A. Baryakh
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
23 shared publications - Elena N. Misyurina
Moscow City Clinical Hospital No. 52, Moscow Healthcare Department; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
23 shared publications - Tatyana S. Chudnova
City Clinical Hospital No. 52, Moscow Healthcare Department. Moscow, Russian Federation;I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University). Moscow, Russian Federation; Moscow Clinical Science and Research Center 52,Moscow,Russia; Department of Hematology,Sechenov University,Moscow,Russia; Vavilov Institute of General Genetics,Moscow,Russia, Russia
22 shared publications - Tatyana Nikolaevna Tolstykh
Moscow City Clinical Hospital No. 52, Moscow Healthcare Department
21 shared publications - Konstantin V. Yatskov
City Clinical Hospital No. 52, 3 Pekhotnaya ul., Moscow, Russian Federation, 123182
20 shared publications - Marat Albertovich Mingalimov
Moscow City Clinical Hospital No. 52, Moscow Healthcare Department
20 shared publications
Latest Publications
- Open Access
- 25 June 2026
- Published by Publishing House ABV Press in Oncohematology
- Vol. 21 (2) , 14-24
First-line antitumor therapy for diffuse large B-cell lymphoma: results of the Moscow oncology registry analysis from 2022 to 2025
Aim. To evaluate the structure and effectiveness of therapy for newly diagnosed diffuse large B-cell lymphoma (DLBCL) in adults in real clinical practice according to the Moscow Oncology Registry data. Materials and methods. Data from 1060 patients with newly diagnosed DLBCL from the Moscow Oncology Registry who received treatment from 2022 to 2025 in a Moscow healthcare setting were retrospectively analyzed. The median age was 69 years. The majority of patients were in the older age group (60.4 %), with advanced disease stages (70 %), non-GCB subtypes (60 %), and high risk according to the international prognostic index (67 %). Of all patients included, 62.1 % received immunochemotherapy according to the R-CHOP program (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone), 12.6 % received R-DA-EPOCH (rituximab, etoposide, prednisolone, vincristine, cyclophosphamide, doxorubicin), 2.6 % received intensive regimens, 14.7 % received R-miniCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone in reduced doses), 7.8 % received RB (rituximab, bendamustine) or R-CVP (rituximab, cyclophosphamide, vincristine, prednisolone). Results. In the overall patient cohort (n = 1060), the objective response rate was 79.7 % (n = 845). Complete metabolic response was achieved by 66.4 % (n = 704) of patients. The complete response rate varied depending on the treatment regimen: in the R-CHOP group it was 68.4 % (n = 451), when using R-DA-EPOCH – 69.4 % (n = 93), intensive regimens – 89.3 % (n = 25). Among patients receiving R-miniCHOP, complete response was achieved in 62.2 % (n = 97) of cases, while in the RB / R-CVP group this rate was the lowest and amounted to 45.8 % (n = 38). With a median follow-up of 24 months, the 2-year overall survival in the total group was 70 % (95 % confidence interval 67–73), and the 2-year progression-free survival was 44 % (95 % confidence interval 40–48). Conclusion. Results of first-line DLBCL therapy efficacy analysis indicate unsatisfactory treatment outcomes, particularly in the high-risk group for early progression. We suggest that biologically targeted antitumor therapy based on the identified tumor genotype represents the most promising clinical approach for patients with newly diagnosed DLBCL.
- 25 June 2026
- Published by Publishing House ABV Press in Oncohematology
- Vol. 21 (2) , 14-24
Open AccessFirst-line antitumor therapy for diffuse large B-cell lymphoma: results of the Moscow oncology registry analysis from 2022 to 2025
Aim. To evaluate the structure and effectiveness of therapy for newly diagnosed diffuse large B-cell lymphoma (DLBCL) in adults in real clinical practice according to the Moscow Oncology Registry data. Materials and methods. Data from 1060 patients with newly diagnosed DLBCL from the Moscow Oncology Registry who received treatment from 2022 to 2025 in a Moscow healthcare setting were retrospectively analyzed. The median age was 69 years. The majority of patients were in the older age group (60.4 %), with advanced disease stages (70 %), non-GCB subtypes (60 %), and high risk according to the international prognostic index (67 %). Of all patients included, 62.1 % received immunochemotherapy according to the R-CHOP program (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone), 12.6 % received R-DA-EPOCH (rituximab, etoposide, prednisolone, vincristine, cyclophosphamide, doxorubicin), 2.6 % received intensive regimens, 14.7 % received R-miniCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone in reduced doses), 7.8 % received RB (rituximab, bendamustine) or R-CVP (rituximab, cyclophosphamide, vincristine, prednisolone). Results. In the overall patient cohort (n = 1060), the objective response rate was 79.7 % (n = 845). Complete metabolic response was achieved by 66.4 % (n = 704) of patients. The complete response rate varied depending on the treatment regimen: in the R-CHOP group it was 68.4 % (n = 451), when using R-DA-EPOCH – 69.4 % (n = 93), intensive regimens – 89.3 % (n = 25). Among patients receiving R-miniCHOP, complete response was achieved in 62.2 % (n = 97) of cases, while in the RB / R-CVP group this rate was the lowest and amounted to 45.8 % (n = 38). With a median follow-up of 24 months, the 2-year overall survival in the total group was 70 % (95 % confidence interval 67–73), and the 2-year progression-free survival was 44 % (95 % confidence interval 40–48). Conclusion. Results of first-line DLBCL therapy efficacy analysis indicate unsatisfactory treatment outcomes, particularly in the high-risk group for early progression. We suggest that biologically targeted antitumor therapy based on the identified tumor genotype represents the most promising clinical approach for patients with newly diagnosed DLBCL.
- Open Access
- 10 December 2025
- Published by Publishing House ABV Press in Oncohematology
- Vol. 20 (4) , 41-50
Multiple myeloma: a retrospective analysis of clinical outcomes based on the patient registry of the Moscow City Clinical Hospital No. 52 (2022–2025)
Background. Multiple myeloma (MM) is the second most common oncohematological disease among malignant tumors of the hematopoietic and lymphoid tissues. According to epidemiological data, MM accounts for approximately 10–12 % of all hematological malignancies. An analysis of the main clinical parameters and treatment outcomes was conducted in patients with MM included in the registry of the Moscow Clinical Research Center “Hospital 52” in 2022–2025. Aim. To evaluate the clinical and hematological profile of MM patients, as well as to analyze the effectiveness of first-line antitumor therapy, including standard treatment regimens and high-dose chemotherapy programs followed by autologous hematopoietic stem cell transplantation. Materials and methods. The observational retrospective study included 325 patients with newly diagnosed MM: 147 (45.2 %) men, 178 (54.8 %) women. The median age at diagnosis was 67 (22–92) years. The number of patients aged 65 years and older was 194 (59.7 %). Antitumor therapy was carried out according to current clinical guidelines. In the first line of therapy, bortezomib was most often used, in the second – lenalidomide and monoclonal antibodies, in the third – monoclonal antibodies. Results. According to the International Staging System, 62.2 % of patients had stage III disease. Myeloma nephropathy was detected in 28.9 % of patients, with 20.3 % requiring programmed dialysis. Autologous hematopoietic stem cell transplantation was performed in 30.8 % of patients. Response to induction therapy: complete remission – 8.0 %; very good partial remission – 27.7 %; partial remission – 24.6 %. The best response rates were achieved with the use of monoclonal antibodies (66.6 % – complete remission + very good partial remission). With a median follow-up of 12.6 months, 1-year overall survival was 83.9 % (95 % confidence interval 82.3–85.4), 1-year progression-free survival was 75.8 % (95 % confidence interval 73.9–77.6). Conclusion. Using registry data allows us to characterize the MM patient population, evaluate the effectiveness of patient treatment, plan the work of the hematology center, forecast the funds required for the purchase of medications, and improve the organizational aspects of the hematology service in a multidisciplinary institution.
- 10 December 2025
- Published by Publishing House ABV Press in Oncohematology
- Vol. 20 (4) , 41-50
Open AccessMultiple myeloma: a retrospective analysis of clinical outcomes based on the patient registry of the Moscow City Clinical Hospital No. 52 (2022–2025)
Background. Multiple myeloma (MM) is the second most common oncohematological disease among malignant tumors of the hematopoietic and lymphoid tissues. According to epidemiological data, MM accounts for approximately 10–12 % of all hematological malignancies. An analysis of the main clinical parameters and treatment outcomes was conducted in patients with MM included in the registry of the Moscow Clinical Research Center “Hospital 52” in 2022–2025. Aim. To evaluate the clinical and hematological profile of MM patients, as well as to analyze the effectiveness of first-line antitumor therapy, including standard treatment regimens and high-dose chemotherapy programs followed by autologous hematopoietic stem cell transplantation. Materials and methods. The observational retrospective study included 325 patients with newly diagnosed MM: 147 (45.2 %) men, 178 (54.8 %) women. The median age at diagnosis was 67 (22–92) years. The number of patients aged 65 years and older was 194 (59.7 %). Antitumor therapy was carried out according to current clinical guidelines. In the first line of therapy, bortezomib was most often used, in the second – lenalidomide and monoclonal antibodies, in the third – monoclonal antibodies. Results. According to the International Staging System, 62.2 % of patients had stage III disease. Myeloma nephropathy was detected in 28.9 % of patients, with 20.3 % requiring programmed dialysis. Autologous hematopoietic stem cell transplantation was performed in 30.8 % of patients. Response to induction therapy: complete remission – 8.0 %; very good partial remission – 27.7 %; partial remission – 24.6 %. The best response rates were achieved with the use of monoclonal antibodies (66.6 % – complete remission + very good partial remission). With a median follow-up of 12.6 months, 1-year overall survival was 83.9 % (95 % confidence interval 82.3–85.4), 1-year progression-free survival was 75.8 % (95 % confidence interval 73.9–77.6). Conclusion. Using registry data allows us to characterize the MM patient population, evaluate the effectiveness of patient treatment, plan the work of the hematology center, forecast the funds required for the purchase of medications, and improve the organizational aspects of the hematology service in a multidisciplinary institution.
- Open Access
- 11 September 2025
- Published by Publishing House ABV Press in Oncohematology
- Vol. 20 (3) , 22-26
Experience with acalabrutinib as a component of molecularly adapted antitumor therapy according to the R-CHOP-X protocol in patients with newly diagnosed diffuse large B-cell lymphoma
Background. Despite tremendous progress in understanding tumor biology, the R-CHOP protocol remains the standard of care for diffuse large B-cell lymphoma (DLBCL). To date, six genetic variants of DLBCL have been identified, the most unfavorable of which when using standard therapy are N1, MCD and BN2, which dictates the need to optimize the treatment of these DLBCL subtypes.Aim. To evaluate the efficacy and toxicity of Acala-R-CHOP regimen in induction therapy in patients with newly diagnosed DLBCL.Materials and methods. The study included 15 patients who received Acala-R-CHOP program as part of the first-line therapy. This antitumor regimen was used for verified genotypes N1, MCD and BN2. The median age was 64 (38–78) years. The incidence of genetic variants in the considered cohort of patients: MCD – 13 % (n = 2), N1 – 74 % (n = 11), BN2 – 13 % (n = 2).Results. Fifteen patients completed the therapy. The overall and complete metabolic response rates were 100 %. Toxicity was moderate, quite manageable and manifested mainly as myelosuppression.Conclusion. The efficacy of Acala-R-CHOP therapy in patients with MCD, N1, and BN2 DLBCL genotypes is high with a low toxicity profile. However, longer follow-up periods are needed to assess the long-term results in this unfavorable group of patients.
- 11 September 2025
- Published by Publishing House ABV Press in Oncohematology
- Vol. 20 (3) , 22-26
Open AccessExperience with acalabrutinib as a component of molecularly adapted antitumor therapy according to the R-CHOP-X protocol in patients with newly diagnosed diffuse large B-cell lymphoma
Background. Despite tremendous progress in understanding tumor biology, the R-CHOP protocol remains the standard of care for diffuse large B-cell lymphoma (DLBCL). To date, six genetic variants of DLBCL have been identified, the most unfavorable of which when using standard therapy are N1, MCD and BN2, which dictates the need to optimize the treatment of these DLBCL subtypes.Aim. To evaluate the efficacy and toxicity of Acala-R-CHOP regimen in induction therapy in patients with newly diagnosed DLBCL.Materials and methods. The study included 15 patients who received Acala-R-CHOP program as part of the first-line therapy. This antitumor regimen was used for verified genotypes N1, MCD and BN2. The median age was 64 (38–78) years. The incidence of genetic variants in the considered cohort of patients: MCD – 13 % (n = 2), N1 – 74 % (n = 11), BN2 – 13 % (n = 2).Results. Fifteen patients completed the therapy. The overall and complete metabolic response rates were 100 %. Toxicity was moderate, quite manageable and manifested mainly as myelosuppression.Conclusion. The efficacy of Acala-R-CHOP therapy in patients with MCD, N1, and BN2 DLBCL genotypes is high with a low toxicity profile. However, longer follow-up periods are needed to assess the long-term results in this unfavorable group of patients.
- Open Access
- 11 September 2025
- Published by Publishing House ABV Press in Oncohematology
- Vol. 20 (3) , 16-21
Molecular phenotype of diffuse large B-cell lymphoma as a basis for a personalized treatment approach of elderly patients
Background. The use of molecular genetic profiling in clinical practice and the registration of immunotargeted agents have undoubtedly led to the development of a personalized approach in oncohematology, with diffuse large B-cell lymphoma (DLBCL) being no exception. Elderly patients represent a complex group of patients with DLBCL, which leads to difficulties in treatment due to their comorbidity.Aim. To evaluate the efficacy, tolerability and safety of an individualized approach based on the mutational landscape in elderly patients with newly diagnosed DLBCL.Materials and methods. The clinical study included 10 elderly patients with newly diagnosed DLBCL. The median age was 68 (65–78) years. Eight patients were classified as being at high risk of early progression according to the international prognostic index. The frequency of genotypes in the considered cohort of elderly patients: MCD – 1 (10 %), N1 – 3 (30 %), BN2 – 1 (10 %), EZB – 2 (20 %), NOS – 3 (30 %).Results. Overall and complete metabolic response rates were 100 %. Clinically significant hematological toxicity depending on the number of cycles (n = 60): grade III–IV neutropenia in 5 cycles, grade III–IV thrombocytopenia in 2, grade III–IV anemia in 3. Non-hematological toxicity did not exceed grades I–II.Conclusion. High efficacy and low toxicity profile of a personalized approach in elderly patients with newly diagnosed DLBCL were demonstrated. The obtained preliminary results indicate the possibility of continuing the developed clinical study of elderly patients with DLBCL.
- 11 September 2025
- Published by Publishing House ABV Press in Oncohematology
- Vol. 20 (3) , 16-21
Open AccessMolecular phenotype of diffuse large B-cell lymphoma as a basis for a personalized treatment approach of elderly patients
Background. The use of molecular genetic profiling in clinical practice and the registration of immunotargeted agents have undoubtedly led to the development of a personalized approach in oncohematology, with diffuse large B-cell lymphoma (DLBCL) being no exception. Elderly patients represent a complex group of patients with DLBCL, which leads to difficulties in treatment due to their comorbidity.Aim. To evaluate the efficacy, tolerability and safety of an individualized approach based on the mutational landscape in elderly patients with newly diagnosed DLBCL.Materials and methods. The clinical study included 10 elderly patients with newly diagnosed DLBCL. The median age was 68 (65–78) years. Eight patients were classified as being at high risk of early progression according to the international prognostic index. The frequency of genotypes in the considered cohort of elderly patients: MCD – 1 (10 %), N1 – 3 (30 %), BN2 – 1 (10 %), EZB – 2 (20 %), NOS – 3 (30 %).Results. Overall and complete metabolic response rates were 100 %. Clinically significant hematological toxicity depending on the number of cycles (n = 60): grade III–IV neutropenia in 5 cycles, grade III–IV thrombocytopenia in 2, grade III–IV anemia in 3. Non-hematological toxicity did not exceed grades I–II.Conclusion. High efficacy and low toxicity profile of a personalized approach in elderly patients with newly diagnosed DLBCL were demonstrated. The obtained preliminary results indicate the possibility of continuing the developed clinical study of elderly patients with DLBCL.
- Open Access
- 1 July 2025
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 18 (3) , 242-249
Myeloid Sarcoma with Skin and Spinal Lesions and KRAS Gene Mutation, Complicated by Secondary Hemophagocytic Syndrome: A Case Report and Literature Review
Myeloid sarcoma (MS) is a rare hematologic tumor of immature myeloid cells with lesions located outside the bone marrow. The disease can develop de novo as extramedullary myeloid tumor, be a manifestation of acute myeloid leukemia (AML) or be diagnosed as an AML relapse after previously achieved remission. MS occurs in all age groups, although more commonly in elderly people. Diagnosis is based on immunomorphological and molecular genetic analyses of the tumor tissue. The most effective treatment regimens in MS are those used for AML therapy with subsequent allogeneic hematopoietic stem cell transplantation provided that the first complete remission was achieved. In addition to that, radiotherapy as well as biological and targeted drugs are administered. Nevertheless, the prognosis of the disease remains generally unfavorable. The present paper reports a clinical case of MS with KRAS mutation, tumor skin and Th5–Th6 lesions, spinal cord compression, and developing flaccid paraplegia. The patient received chemotherapies of varying intensity as well as hypomethylating agents combined with venetoclax and the targeted drug trametinib. The course of the disease was complicated by secondary hemophagocytic syndrome (SHS). The present case report demonstrates the challenges of both diagnosis and treatment of this rare and poor-prognosis extramedullary myeloid tumor complicated by SHS.
- 1 July 2025
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 18 (3) , 242-249
Open AccessMyeloid Sarcoma with Skin and Spinal Lesions and KRAS Gene Mutation, Complicated by Secondary Hemophagocytic Syndrome: A Case Report and Literature Review
Myeloid sarcoma (MS) is a rare hematologic tumor of immature myeloid cells with lesions located outside the bone marrow. The disease can develop de novo as extramedullary myeloid tumor, be a manifestation of acute myeloid leukemia (AML) or be diagnosed as an AML relapse after previously achieved remission. MS occurs in all age groups, although more commonly in elderly people. Diagnosis is based on immunomorphological and molecular genetic analyses of the tumor tissue. The most effective treatment regimens in MS are those used for AML therapy with subsequent allogeneic hematopoietic stem cell transplantation provided that the first complete remission was achieved. In addition to that, radiotherapy as well as biological and targeted drugs are administered. Nevertheless, the prognosis of the disease remains generally unfavorable. The present paper reports a clinical case of MS with KRAS mutation, tumor skin and Th5–Th6 lesions, spinal cord compression, and developing flaccid paraplegia. The patient received chemotherapies of varying intensity as well as hypomethylating agents combined with venetoclax and the targeted drug trametinib. The course of the disease was complicated by secondary hemophagocytic syndrome (SHS). The present case report demonstrates the challenges of both diagnosis and treatment of this rare and poor-prognosis extramedullary myeloid tumor complicated by SHS.
- Open Access
- 1 April 2025
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 18 (2) , 171-176
Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma Complicated by Dialysis-Dependent Renal Failure
BACKGROUND. Renal failures, among them dialysis-dependent kidney disease, are common complications of multiple myeloma (ММ). Hemodialysis (HD) independence is achieved in only 20 % of standard induction therapy recipients. The survival of program HD patients remains unsatisfactory. Autologous hematopoietic stem cell transplantation (auto-HSCT) is usually planned and performed in young MM patients. However, the program HD patients are often excluded from the high-dose chemotherapy protocols with subsequent auto-HSCT due to the therapy associated toxicity risk. AIM. To assess the efficacy and safety of auto-HSCT in MM complicated by dialysis-dependent renal failure. MATERIALS & METHODS. In the period from 2015 to 2022, 14 program HD patients (8 men and 6 women) received auto-HSCT at the City Clinical Hospital No. 52. The median age was 53 years (range 43–66 years). In two patients, tandem transplantation was performed. Melphalan 140 mg/m2 (n = 10) was administered for pre-transplant conditioning. In 4 patients, bendamustine 200 mg/m2 was added to melphalan in the conditioning regimen. The median transfused СD34+ cell count was 3.61 × 106/kg (range 1.34–9.69 × 106/kg). By the time of completing bortezomib and/or lenalidomide induction therapy, complete remission (CR) was achieved in 5 patients, other 5 patients showed very good partial remission (VGPR), and in 4 patients partial remission (PR) was registered. RESULTS. As reported by the control follow-up on Day +100 after auto-HSCT, all patients demonstrated further deepening of antitumor response. By this time, CR in 11 (79 %) patients and VGPR in 2 (14 %) patients were registered, whereas 1 (7 %) patient maintained PR. Renal response and HD independence were achieved in 8 (57 %) out of 14 patients enrolled in the trial. In the total group (n = 14), the 3-year event-free survival was 50 % and overall survival was 78 %. CONCLUSION. Dialysis-dependent renal failure in MM patients is no contraindication to auto-HSCT. The latter will improve chemotherapy outcomes and make it possible to achieve renal response and HD independence.
- 1 April 2025
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 18 (2) , 171-176
Open AccessAutologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma Complicated by Dialysis-Dependent Renal Failure
BACKGROUND. Renal failures, among them dialysis-dependent kidney disease, are common complications of multiple myeloma (ММ). Hemodialysis (HD) independence is achieved in only 20 % of standard induction therapy recipients. The survival of program HD patients remains unsatisfactory. Autologous hematopoietic stem cell transplantation (auto-HSCT) is usually planned and performed in young MM patients. However, the program HD patients are often excluded from the high-dose chemotherapy protocols with subsequent auto-HSCT due to the therapy associated toxicity risk. AIM. To assess the efficacy and safety of auto-HSCT in MM complicated by dialysis-dependent renal failure. MATERIALS & METHODS. In the period from 2015 to 2022, 14 program HD patients (8 men and 6 women) received auto-HSCT at the City Clinical Hospital No. 52. The median age was 53 years (range 43–66 years). In two patients, tandem transplantation was performed. Melphalan 140 mg/m2 (n = 10) was administered for pre-transplant conditioning. In 4 patients, bendamustine 200 mg/m2 was added to melphalan in the conditioning regimen. The median transfused СD34+ cell count was 3.61 × 106/kg (range 1.34–9.69 × 106/kg). By the time of completing bortezomib and/or lenalidomide induction therapy, complete remission (CR) was achieved in 5 patients, other 5 patients showed very good partial remission (VGPR), and in 4 patients partial remission (PR) was registered. RESULTS. As reported by the control follow-up on Day +100 after auto-HSCT, all patients demonstrated further deepening of antitumor response. By this time, CR in 11 (79 %) patients and VGPR in 2 (14 %) patients were registered, whereas 1 (7 %) patient maintained PR. Renal response and HD independence were achieved in 8 (57 %) out of 14 patients enrolled in the trial. In the total group (n = 14), the 3-year event-free survival was 50 % and overall survival was 78 %. CONCLUSION. Dialysis-dependent renal failure in MM patients is no contraindication to auto-HSCT. The latter will improve chemotherapy outcomes and make it possible to achieve renal response and HD independence.
- Open Access
- 1 April 2025
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 18 (2) , 177-183
Personalized Approach to Treatment of Newly Diagnosed Diffuse Large B-Cell Lymphoma Patients with Respect to Molecular Landscape: A Case Report and Literature Review
The term “Diffuse Large B-Cell Lymphoma” (DLBCL) covers an extremely heterogeneous range of aggressive hematological tumors of lymphoid origin. The recommended standard first-line treatment R-CHOP is still the leading therapy for newly diagnosed DLBCL. However, the outcomes of the unified approach to chemotherapy disregarding a high clinical and molecular genetic heterogeneity of this variant of non-Hodgkin lymphoma are evaluated as unsatisfactory. This paper is the first in the Russian Federation to report the personal experience with the use of the combination of R-CHOP regimen as basic therapy and chemotherapeutic agent acalabrutinib, one of Bruton tyrosine kinase inhibitors, with respect to Sanger sequencing results.
- 1 April 2025
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 18 (2) , 177-183
Open AccessPersonalized Approach to Treatment of Newly Diagnosed Diffuse Large B-Cell Lymphoma Patients with Respect to Molecular Landscape: A Case Report and Literature Review
The term “Diffuse Large B-Cell Lymphoma” (DLBCL) covers an extremely heterogeneous range of aggressive hematological tumors of lymphoid origin. The recommended standard first-line treatment R-CHOP is still the leading therapy for newly diagnosed DLBCL. However, the outcomes of the unified approach to chemotherapy disregarding a high clinical and molecular genetic heterogeneity of this variant of non-Hodgkin lymphoma are evaluated as unsatisfactory. This paper is the first in the Russian Federation to report the personal experience with the use of the combination of R-CHOP regimen as basic therapy and chemotherapeutic agent acalabrutinib, one of Bruton tyrosine kinase inhibitors, with respect to Sanger sequencing results.
- Open Access
- 10 December 2024
- Published by Publishing House ABV Press in Oncohematology
- Vol. 19 (4) , 84-92
Personalized genotype-directed antitumor therapy for newly diagnosed diffuse large B-cell lymphoma: efficacy and toxicity of the R-CHOP-X protocol in a single-center, non-randomized, prospective clinical trial (first results)
Background. Diffuse large B-cell lymphoma (DLBCL) is a potentially curable biologically heterogeneous lymphatic tumor. Standard R-CHOP therapy shows disappointing results, both immediate and longterm. To improve efficacy without additional toxicity, it is worth considering the possibility of using biologically oriented therapy.Aim. To evaluate the clinical efficacy and toxicity of the genotypedirected R-CHOP-X in patients with newly diagnosed DLBCL in real clinical practice.Materials and methods. A single-center prospective interventional clinical study included 30 patients with newly diagnosed DLBCL between September 2023 and September 2024. The median age was 60 (38–78) years. According to the international prognostic index, 23 (77 %) patients were classified as having a high risk of progression. Genotype incidence in the study cohort: MCD – 7 %, N1 – 20 %, BN2 – 7 %, EZB– 16 %, ST2 – 7 %, NOS – 43 %.Results. 30 patients received personalized genotype-directed therapy. Of these, 21 (70 %) patients completed treatment: the overall response rate was 100 % (complete metabolic response – 100 %). 9 (30 %) patients continue therapy: the overall response rate is 100 %. At 12 months, overall survival and progression-free survival were 100 % (95 % confidence interval 100 %). Hematological toxicity was assessed depending on the number of cycles (n = 144): grade III–I neutropenia was detected in 7 % of cycles, grade III–I anemia and grade III–I thrombocytopenia in 1.4 and 3.5 % of cycles, respectively. Non-hematological toxicity was generally grade ≤I–II.Conclusion. The results of this clinical trial are promising and provide preliminary evidence for the benefit of personalized genotype-directed antitumor therapy in newly diagnosed DLBCL. This therapeutic strategy demonstrates high clinical efficacy, particularly in the main target group – DLBCL with a high risk of progression with low toxicity. Further randomized studies are needed to confirm the effectiveness and implement the new approach in routine clinical practice.
- 10 December 2024
- Published by Publishing House ABV Press in Oncohematology
- Vol. 19 (4) , 84-92
Open AccessPersonalized genotype-directed antitumor therapy for newly diagnosed diffuse large B-cell lymphoma: efficacy and toxicity of the R-CHOP-X protocol in a single-center, non-randomized, prospective clinical trial (first results)
Background. Diffuse large B-cell lymphoma (DLBCL) is a potentially curable biologically heterogeneous lymphatic tumor. Standard R-CHOP therapy shows disappointing results, both immediate and longterm. To improve efficacy without additional toxicity, it is worth considering the possibility of using biologically oriented therapy.Aim. To evaluate the clinical efficacy and toxicity of the genotypedirected R-CHOP-X in patients with newly diagnosed DLBCL in real clinical practice.Materials and methods. A single-center prospective interventional clinical study included 30 patients with newly diagnosed DLBCL between September 2023 and September 2024. The median age was 60 (38–78) years. According to the international prognostic index, 23 (77 %) patients were classified as having a high risk of progression. Genotype incidence in the study cohort: MCD – 7 %, N1 – 20 %, BN2 – 7 %, EZB– 16 %, ST2 – 7 %, NOS – 43 %.Results. 30 patients received personalized genotype-directed therapy. Of these, 21 (70 %) patients completed treatment: the overall response rate was 100 % (complete metabolic response – 100 %). 9 (30 %) patients continue therapy: the overall response rate is 100 %. At 12 months, overall survival and progression-free survival were 100 % (95 % confidence interval 100 %). Hematological toxicity was assessed depending on the number of cycles (n = 144): grade III–I neutropenia was detected in 7 % of cycles, grade III–I anemia and grade III–I thrombocytopenia in 1.4 and 3.5 % of cycles, respectively. Non-hematological toxicity was generally grade ≤I–II.Conclusion. The results of this clinical trial are promising and provide preliminary evidence for the benefit of personalized genotype-directed antitumor therapy in newly diagnosed DLBCL. This therapeutic strategy demonstrates high clinical efficacy, particularly in the main target group – DLBCL with a high risk of progression with low toxicity. Further randomized studies are needed to confirm the effectiveness and implement the new approach in routine clinical practice.
- Open Access
- 9 December 2024
- Published by Publishing House ABV Press in Oncohematology
- Vol. 19 (4) , 52-72
Nivolumab-containing therapy in patients with newly diagnosed classical Hodgkin lymphoma: own clinical observations and literature review
Classical Hodgkin’s lymphoma (cHL) is a lymphoproliferative disease characterized by the presence of Hodgkin anderezovsky–Reed–Sternberg cells and a tumor microenvironment. Currently, much attention is paid to the microenvironment in cLH. A detailed understanding of the interaction between the tumor and its microenvironment opens up prospects for the cHL diagnosis and treatment. Innovative immunotherapeutic agents such as nivolumab make it possible to control and activate the immune response. Despite the high efficiency of standard protocols in young patients, therapy intensification is associated with organ toxicity and the development of secondary malignant neoplasms. At the same time, in elderly patients, the results of generally accepted antitumor treatment protocols should be considered suboptimal. In the last decade, the treatment of refractory cHL has improved significantly due to the use of immune checkpoint inhibitors.Taking into account the above, the priority issue in modern clinical hematology is to improve cHL treatment strategies not only in elderly but also in young patients by maintaining a balance between high efficacy and low toxicity. Moreover, the inclusion of nivolumab in first-line therapy is not only pathogenetically justified and effective, but also safe. The article presents data from clinical observations of the successful nivolumab use in combination with chemotherapy in patients with newly diagnosed cHL.
- 9 December 2024
- Published by Publishing House ABV Press in Oncohematology
- Vol. 19 (4) , 52-72
Open AccessNivolumab-containing therapy in patients with newly diagnosed classical Hodgkin lymphoma: own clinical observations and literature review
Classical Hodgkin’s lymphoma (cHL) is a lymphoproliferative disease characterized by the presence of Hodgkin anderezovsky–Reed–Sternberg cells and a tumor microenvironment. Currently, much attention is paid to the microenvironment in cLH. A detailed understanding of the interaction between the tumor and its microenvironment opens up prospects for the cHL diagnosis and treatment. Innovative immunotherapeutic agents such as nivolumab make it possible to control and activate the immune response. Despite the high efficiency of standard protocols in young patients, therapy intensification is associated with organ toxicity and the development of secondary malignant neoplasms. At the same time, in elderly patients, the results of generally accepted antitumor treatment protocols should be considered suboptimal. In the last decade, the treatment of refractory cHL has improved significantly due to the use of immune checkpoint inhibitors.Taking into account the above, the priority issue in modern clinical hematology is to improve cHL treatment strategies not only in elderly but also in young patients by maintaining a balance between high efficacy and low toxicity. Moreover, the inclusion of nivolumab in first-line therapy is not only pathogenetically justified and effective, but also safe. The article presents data from clinical observations of the successful nivolumab use in combination with chemotherapy in patients with newly diagnosed cHL.
- Open Access
- 3 September 2024
- Published by Publishing House ABV Press in Oncohematology
- Vol. 19 (3) , 206-214
COVID-19 in patients with acute lymphoblastic leukemia
Background. Patients with acute lymphoblastic leukemia (ALL) have been the most vulnerable group of patients at risk of severe and extremely severe COVID-19 throughout the coronavirus pandemic. Secondary immunodeficiency due to acute leukemia, as well as antitumor treatment, predisposes to the development of a more severe infection, as well as long-term SARS-CoV-2 persistence even after complete regression of COVID-19 symptoms. Thus, although after the emergence of the SARS-CoV-2 Omicron variant, coronavirus infection began to occur predominantly in a mild form, COVID-19 in ALL patients remains an urgent problem.Aim. To assess hospital survival of patients with ALL and concomitant coronavirus infection, to identify predictors of death and to evaluate the impact of program antitumor therapy on the outcome in this cohort of patients.Materials and methods. A retrospective analysis of ALL patients hospitalized in City Clinical Hospital No. 52 with coronavirus infection from February 2020 to December 2022 was conducted. Diagnosis and treatment of patients were carried out in accordance with valid at the time of hospitalization temporary guidelines “Prevention, diagnosis and treatment of new coronavirus infection (COVID-19)”. Univariate and multivariate regression analyses were performed to identify predictors of mortality in patients with ALL and COVID-19. Survival analysis was performed using the Kaplan–Meier method. A p 0.05 was considered statistically significant.Results. The study included 60 patients with ALL and concomitant coronavirus infection (30 men and 30 women). The median age was 42 years. Extremely severe coronavirus infection was observed in 25 % of patients in 2020–2021 and in 5 % of patients in 2022. Forty five patients received chemotherapy a month before hospitalization for COVID-19, 23 patients – during hospitalization. In-hospital mortality was 25 % (11 patients in 2020, 4 patients in 2021). The cause of death in 9 (60 %) cases was severe coronavirus infection; 4 (27 %) patients died as a result of severe bacterial complications, 2 (13 %) – due to ALL progression. In multivariate regression analysis, the following predictors had a statistically significant impact on the outcome: ALL relapse, absence of seroconversion at the time of outcome (anti-SARS-CoV-2 IgG level at the time of outcome 50 U/mL). When analyzing the impact of chemotherapy administered a month before or during hospitalization due to coronavirus infection, statistically significant values were not obtained for any of the factors.Conclusion. Considering the obtained results and international recommendations for the treatment of ALL patients with COVID-19, the decision on antitumor treatment for ALL patients when SARS-CoV-2 RNA is detected by polymerase chain reaction in an oropharyngeal swab should be made individually depending on the patient’s age, clinical manifestations of coronavirus infection, ALL status and the antitumor therapy phase. In addition, given the reduced antiviral response in ALL patients, special attention should be paid to the prevention of SARS-CoV-2 infection, and in case of disease development, passive immunization methods (virus-neutralizing monoclonal antibodies) should be considered as antiviral therapy.
- 3 September 2024
- Published by Publishing House ABV Press in Oncohematology
- Vol. 19 (3) , 206-214
Open AccessCOVID-19 in patients with acute lymphoblastic leukemia
Background. Patients with acute lymphoblastic leukemia (ALL) have been the most vulnerable group of patients at risk of severe and extremely severe COVID-19 throughout the coronavirus pandemic. Secondary immunodeficiency due to acute leukemia, as well as antitumor treatment, predisposes to the development of a more severe infection, as well as long-term SARS-CoV-2 persistence even after complete regression of COVID-19 symptoms. Thus, although after the emergence of the SARS-CoV-2 Omicron variant, coronavirus infection began to occur predominantly in a mild form, COVID-19 in ALL patients remains an urgent problem.Aim. To assess hospital survival of patients with ALL and concomitant coronavirus infection, to identify predictors of death and to evaluate the impact of program antitumor therapy on the outcome in this cohort of patients.Materials and methods. A retrospective analysis of ALL patients hospitalized in City Clinical Hospital No. 52 with coronavirus infection from February 2020 to December 2022 was conducted. Diagnosis and treatment of patients were carried out in accordance with valid at the time of hospitalization temporary guidelines “Prevention, diagnosis and treatment of new coronavirus infection (COVID-19)”. Univariate and multivariate regression analyses were performed to identify predictors of mortality in patients with ALL and COVID-19. Survival analysis was performed using the Kaplan–Meier method. A p 0.05 was considered statistically significant.Results. The study included 60 patients with ALL and concomitant coronavirus infection (30 men and 30 women). The median age was 42 years. Extremely severe coronavirus infection was observed in 25 % of patients in 2020–2021 and in 5 % of patients in 2022. Forty five patients received chemotherapy a month before hospitalization for COVID-19, 23 patients – during hospitalization. In-hospital mortality was 25 % (11 patients in 2020, 4 patients in 2021). The cause of death in 9 (60 %) cases was severe coronavirus infection; 4 (27 %) patients died as a result of severe bacterial complications, 2 (13 %) – due to ALL progression. In multivariate regression analysis, the following predictors had a statistically significant impact on the outcome: ALL relapse, absence of seroconversion at the time of outcome (anti-SARS-CoV-2 IgG level at the time of outcome 50 U/mL). When analyzing the impact of chemotherapy administered a month before or during hospitalization due to coronavirus infection, statistically significant values were not obtained for any of the factors.Conclusion. Considering the obtained results and international recommendations for the treatment of ALL patients with COVID-19, the decision on antitumor treatment for ALL patients when SARS-CoV-2 RNA is detected by polymerase chain reaction in an oropharyngeal swab should be made individually depending on the patient’s age, clinical manifestations of coronavirus infection, ALL status and the antitumor therapy phase. In addition, given the reduced antiviral response in ALL patients, special attention should be paid to the prevention of SARS-CoV-2 infection, and in case of disease development, passive immunization methods (virus-neutralizing monoclonal antibodies) should be considered as antiviral therapy.